Park Avenue Securities LLC Acquires 155 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Park Avenue Securities LLC boosted its stake in United Therapeutics Co. (NASDAQ:UTHR) by 11.0% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,562 shares of the biotechnology company’s stock after purchasing an additional 155 shares during the period. Park Avenue Securities LLC’s holdings in United Therapeutics were worth $359,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Rise Advisors LLC bought a new position in shares of United Therapeutics during the first quarter worth about $32,000. GAMMA Investing LLC bought a new position in United Therapeutics during the 4th quarter worth approximately $43,000. Blue Trust Inc. lifted its position in shares of United Therapeutics by 10.0% in the 4th quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 46 shares during the period. Quadrant Capital Group LLC boosted its stake in shares of United Therapeutics by 31.2% in the 4th quarter. Quadrant Capital Group LLC now owns 581 shares of the biotechnology company’s stock valued at $128,000 after purchasing an additional 138 shares during the last quarter. Finally, CWM LLC increased its position in shares of United Therapeutics by 45.7% during the fourth quarter. CWM LLC now owns 670 shares of the biotechnology company’s stock worth $147,000 after buying an additional 210 shares during the period. 94.08% of the stock is owned by institutional investors.

Analyst Ratings Changes

UTHR has been the topic of several recent analyst reports. Oppenheimer boosted their target price on shares of United Therapeutics from $375.00 to $400.00 and gave the company an “outperform” rating in a report on Thursday, May 2nd. JPMorgan Chase & Co. upped their target price on United Therapeutics from $280.00 to $300.00 and gave the company an “overweight” rating in a research report on Tuesday, May 21st. The Goldman Sachs Group lifted their target price on United Therapeutics from $218.00 to $240.00 and gave the stock a “neutral” rating in a report on Friday, May 3rd. Wells Fargo & Company increased their price target on United Therapeutics from $325.00 to $350.00 and gave the stock an “overweight” rating in a report on Wednesday, June 12th. Finally, StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 20th. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $312.22.

Insider Activity at United Therapeutics

In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $232.05, for a total transaction of $835,380.00. Following the transaction, the chief executive officer now directly owns 130 shares in the company, valued at approximately $30,166.50. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $232.05, for a total value of $835,380.00. Following the completion of the sale, the chief executive officer now owns 130 shares in the company, valued at approximately $30,166.50. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Christopher Causey sold 2,240 shares of the business’s stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $259.91, for a total value of $582,198.40. Following the completion of the transaction, the director now owns 4,185 shares in the company, valued at approximately $1,087,723.35. The disclosure for this sale can be found here. Insiders have sold a total of 126,344 shares of company stock valued at $32,426,462 over the last 90 days. Insiders own 12.50% of the company’s stock.

United Therapeutics Stock Up 0.5 %

United Therapeutics stock opened at $318.55 on Monday. The firm has a market capitalization of $14.13 billion, a price-to-earnings ratio of 15.06, a price-to-earnings-growth ratio of 1.40 and a beta of 0.49. The firm’s fifty day moving average price is $274.77 and its two-hundred day moving average price is $243.95. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $321.80. The company has a current ratio of 3.77, a quick ratio of 3.64 and a debt-to-equity ratio of 0.04.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share for the quarter, beating the consensus estimate of $5.63 by $0.54. The business had revenue of $677.70 million for the quarter, compared to analysts’ expectations of $620.31 million. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The firm’s revenue for the quarter was up 33.7% compared to the same quarter last year. During the same quarter last year, the firm earned $4.86 EPS. On average, equities research analysts predict that United Therapeutics Co. will post 24.73 earnings per share for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.